SCHEMBL9901133

SCHEMBL9901133

O=Cc1ccc(Cc2ccc(Cl)c(C(F)(F)F)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.51
KIF11 P52732 1/20 0.44
PYCR1 P32322 1/20 0.43
ALDH1A1 P00352 1/20 0.43
NPFFR1 Q9GZQ6 2/20 0.42
NPFFR2 Q9Y5X5 2/20 0.42
KDM4A O75164 1/20 0.42
KDM5A P29375 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
KDR P35968 2/20 0.41
GPR84 Q9NQS5 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HSD17B10 Q99714 1/20 0.38
ABCB11 O95342 1/20 0.38
P2RX7 Q99572 1/20 0.38
FAAH O00519 1/20 0.38
MAOB P27338 1/20 0.38
PPARG P37231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10656615 0.86 IDO1 (0.65) IDO1PYCR1KDM4AKDM5AKDM5B
SCHEMBL9904817 0.86 IDO1 (0.50) IDO1PYCR1NPFFR1NPFFR2KDM4A
SCHEMBL40676 0.83 ALDH1A1 (0.57) IDO1KIF11ALDH1A1NPFFR1NPFFR2
SCHEMBL17508145 0.82 KIF11 (0.53) KIF11P2RX7
SCHEMBL1041385 0.81 IDO1 (0.56) IDO1PYCR1KDM4AKDM5AKDM5B
SCHEMBL30861660 0.80 KIF11 (0.63) KIF11ALDH1A1NPFFR1NPFFR2KDR
SCHEMBL17115582 0.80 KIF11 (0.63) KIF11ALDH1A1NPFFR1NPFFR2KDR
SCHEMBL4084168 0.80 IDO1 (0.57) IDO1PYCR1NPFFR1NPFFR2KDM4A
SCHEMBL9900501 0.77 IDO1 (0.51) IDO1PYCR1KDM4AKDM5AKDM5B
SCHEMBL875004 0.76 AR (0.46) KIF11ALDH1A1NPFFR1NPFFR2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
EP-2649050-A1 COMPOUNDS Glaxo Group Limited (GB) 2013-10-16 EP disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
WO-2012075917-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252986-A1 COMPOUNDS LIPG, ENPP2, PLA2G1B IDO1 2470/4885KIF11 4651/4885PYCR1 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.